Neues beim Schlaganfall unter besonderer Berücksichtigung älterer Patienten

Die Prävention, Diagnostik und Therapie zerebraler Durchblutungsstörungen hat in den letzten 30 Jahren immense Fortschritte gemacht. Dazu beigetragen haben die modernen Methoden der zerebralen Bildgebung und die Versorgung der Patienten auf Stroke Units. Diese Übersicht fasst die wichtigsten wissenschaftlichen und klinischen Erkenntnisse der letzten beiden Jahre zusammen.

Schlüsselwörter

Schlaganfall - ischämischer Insult - Gehirninfarkt - zerebrale Blutung - neurologisches Defizit - Stroke Unit - Hirnblutung

• Literatur

• 1 Statistisches Bundesamt. Todesursachenstatistik Stand 2016. Im Internet: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/_inhalt.html Stand: 19.07.2019
• 2 Feigin VL, Roth GA, Naghavi M. et al. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016; 15: 913-924 doi:10.1016/S1474-4422(16)30073-4
• 3 Rucker V, Wiedmann S, OʼFlaherty M. et al. Decline in regional trends in mortality of stroke subtypes in Germany from 1998 to 2015. Stroke 2018; 49: 2577-2583 doi:10.1161/STROKEAHA.118.023193
• 4 Heuschmann P, Busse O, Wagner M. et al. Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland. Akt Neurol 2010; 37: 333-340
• 5 GBD Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459-480 doi:10.1016/S1474-4422(18)30499-X
• 6 Tibaek M, Dehlendorff C, Jorgensen HS. et al. Increasing incidence of hospitalization for stroke and transient ischemic attack in young adults: a registry-based study. J Am Heart Assoc 2016;
• 7 Weber R, Eyding J, Kitzrow M. et al. Distribution and evolution of acute interventional ischemic stroke treatment in Germany from 2010 to 2016. Neurol Res Pract 2019;
• 8 Adams jr. HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
• 9 Kolominsky-Rabas PL, Wiedmann S, Weingartner M. et al. Time trends in incidence of pathological and etiological stroke subtypes during 16 years: the Erlangen Stroke Project. Neuroepidemiology 2015; 44: 24-29 doi:10.1159/000371353
• 10 Hart RG, Diener HC, Coutts SB. et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429-438 doi:10.1016/S1474-4422(13)70310-7
• 11 Schöberl F, Ringleb PA, Wakili R. et al. Juvenile stroke. Dtsch Arztebl Int 2017; 114: 527-534 doi:10.3238/arztebl.2017.0527
• 12 Wiedmann S, Heuschmann PU, Hillmann S. et al. The quality of acute stroke care- an analysis of evidence-based indicators in 260 000 patients. Dtsch Arztebl Int 2014; 111: 759-765 doi:10.3238/arztebl.2014.0759
• 13 Thomalla G, Simonsen CZ, Boutitie F. et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018; 379: 611-622 doi:10.1056/NEJMoa1804355
• 14 Erbguth F. Stroke Mimics und Stroke Chamäleons – Differenzialdiagnose des Schlaganfalls. Fortschr Neurol Psychiatr 2017; 85: 747-764 doi:10.1055/s-0043-111889
• 15 Nabavi DG, Ossenbrink M, Schinkel M. et al. Aktualisierte Zertifizierungskriterien für regionale und überregionale Stroke-Units in Deutschland. Nervenarzt 2015; 86: 978-988 doi:10.1007/s00115-015-4395-5
• 16 Kallmünzer B, Breuer L, Kahl N. et al. Serious cardiac arrhythmias after stroke: incidence, time course, and predictors-a systematic, prospective analysis. Stroke 2012; 43: 2892-2897 doi:10.1161/STROKEAHA.112.664318
• 17 Häusler KG, Groschel K, Kohrmann M. et al. Position paper on atrial fibrillation detection after ischemic stroke. Working Group Heart and Brain of the German Cardiac Society (DGK) and the German Stroke Society (DSG). Akt Neurol 2018; 45: 93-106 doi:10.1055/s-0043-118476
• 18 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962 doi:10.1093/eurheartj/ehw210
• 19 Camen S, Haeusler K, Schnabel R. Cardiac imaging after ischemic stroke: Echocardiography, CT or MRI?. Herz 2019; 44: 296-303 doi:10.1007/s00059-019-4803-x
• 20 Nogueira RG, Jadhav AP, Haussen DC. et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378: 11-21 doi:10.1056/NEJMoa1706442
• 21 Albers GW, Marks MP, Kemp S. et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018;
• 22 Khatri P, Kleindorfer DO, Devlin T. et al. Effect of alteplase vs. aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: The PRISMS Randomized Clinical Trial. JAMA 2018; 320: 156-166 doi:10.1001/jama.2018.8496
• 23 Thomalla G, Cheng B, Ebinger M. et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 2011; 10: 978-986
• 24 Gaziano JM, Brotons C, Coppolecchia R. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036-1046 doi:10.1016/S0140-6736(18)31924-X
• 25 McNeil JJ, Nelson MR, Woods RL. et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018;
• 26 McNeil JJ, Wolfe R, Woods RL. et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018; 379: 1509-1518 doi:10.1056/NEJMoa1805819
• 27 McNeil JJ, Woods RL, Nelson MR. et al. Effect of Aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018; 379: 1499-1508 doi:10.1056/NEJMoa1800722
• 28 ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;
• 29 Rothwell PM, Cook NR, Gaziano JM. et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387-399 doi:10.1016/S0140-6736(18)31133-4
• 30 Wang Y, Wang Y, Zhao X. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11-19 doi:10.1056/NEJMoa1215340
• 31 Johnston SC, Easton JD, Farrant M. et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;
• 32 Prasad K, Siemieniuk R, Hao Q. et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. BMJ 2018; 363: k5130 doi:10.1136/bmj.k5130
• 33 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330 doi:10.1056/NEJMoa1709118
• 34 Lip GYH, Keshishian A, Li X. et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke 2018; 49: 2933-2944 doi:10.1161/STROKEAHA.118.020232
• 35 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378: 2191-2201 doi:10.1056/NEJMoa1802686
• 36 Boulouis G, Morotti A, Goldstein JN. et al. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry 2017; 88: 339-345
• 37 RIGHT-2 Investigators. Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. Lancet 2019; 393: 1009-1020 doi:10.1016/S0140-6736(19)30194-1
• 38 Kuramatsu JB, Gerner ST, Schellinger PD. et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-836 doi:10.1001/jama.2015.0846
• 39 Steiner T, Poli S, Griebe M. et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016; 15: 566-573 doi:10.1016/S1474-4422(16)00110-1
• 40 Connolly SJ, Crowther M, Eikelboom JW. et al. Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380: 1326-1335 doi:10.1056/NEJMoa1814051
• 41 Gerner ST, Kuramatsu JB, Sembill JA. et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 2018; 83: 186-196 doi:10.1002/ana.25134
• 42 Sprigg N, Flaherty K, Appleton JP. et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018; 391: 2107-2115 doi:10.1016/S0140-6736(18)31033-X
• 43 Hanley DF, Thompson RE, Rosenblum M. et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet 2019; 393: 1021-1032 doi:10.1016/S0140-6736(19)30195-3
• 44 Volbers B, Giede-Jeppe A, Gerner ST. et al. Peak perihemorrhagic edema correlates with functional outcome in intracerebral hemorrhage. Neurology 2018; 90: e1005-e1012
• 45 Hanley DF, Lane K, McBee N. et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 2017; 389: 603-611 doi:10.1016/S0140-6736(16)32410-2
• 46 Kuramatsu JB, Sembill JA, Gerner ST. et al. Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J 2018; 39: 1709-1723
• 47 Sondergaard L, Kasner SE, Rhodes JF. et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377: 1033-1042 doi:10.1056/NEJMoa1707404
• 48 Mas JL, Derumeaux G, Guillon B. et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017; 377: 1011-1021 doi:10.1056/NEJMoa1705915
• 49 Lee PH, Song JK, Kim JS. et al. Cryptogenic Stroke and high-risk patent foramen ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol 2018; 71: 2335-2342 doi:10.1016/j.jacc.2018.02.046
• 50 Saver JL, Carroll JD, Thaler DE. et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377: 1022-1032 doi:10.1056/NEJMoa1610057
• 51 Saver JL, Mattle HP, Thaler D. Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke: a topical review. Stroke 2018; 49: 1541-1548 doi:10.1161/STROKEAHA.117.018153
• 52 Diener HC, Grau AJ, Baldus S. et al. Kryptogener Schlaganfall und offenes Foramen ovale. Nervenarzt 2018; 89: 1143-1153 doi:10.1007/s00115-018-0609-y
• 53 Meier B, Kalesan B, Mattle HP. et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083-1091 doi:10.1056/NEJMoa1211716
• 54 Carroll JD, Saver JL, Thaler DE. et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092-1100 doi:10.1056/NEJMoa1301440
• 55 Furlan AJ, Reisman M, Massaro J. et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991-999
• 56 Ntaios G, Papavasileiou V, Sagris D. et al. Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. Stroke 2018; 49: 412-418 doi:10.1161/STROKEAHA.117.020030
• 57 Röther J, Kohrmann M, Steiner T. et al. PFO-Verschluss bei kryptogenem Schlaganfall – „solllte erwogen werden“!. Nervenarzt 2018; 89: 1154-1155 doi:10.1007/s00115-018-0613-2
• 58 Kohrmann M, Schellinger PD, Tsivgoulis G. et al. Patent foramen ovale: story closed?. J Stroke 2019; 21: 23-30 doi:10.5853/jos.2018.03097
• 59 Kent DM, Ruthazer R, Weimar C. et al. An index to identify stroke-related vs. incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81: 619-625 doi:10.1212/WNL.0b013e3182a08d59
• 60 Kloss M, Grond-Ginsbach C, Ringleb P. et al. Recurrence of cervical artery dissection: An underestimated risk. Neurology 2018; 90: e1372-e1378 doi:10.1212/WNL0000000000005324
• 61 Schlemm L, Nolte CH, Engelter ST. et al. Cervical artery dissection after sports – An analytical evaluation of 190 published cases. Eur Stroke J 2017; 2: 335-345 doi:10.1177/2396987317720544
• 62 Traenka C, Jung S, Gralla J. et al. Endovascular therapy versus intravenous thrombolysis in cervical artery dissection ischemic stroke - Results from the SWISS registry. Eur Stroke J 2018; 3: 47-56 doi:10.1177/2396987317748545
• 63 Tsivgoulis G, Zand R, Katsanos AH. et al. Safety and outcomes of intravenous thrombolysis in dissection-related ischemic stroke: an international multicenter study and comprehensive meta-analysis of reported case series. J Neurol 2015; 262: 2135-2143 doi:10.1007/s00415-015-7829-x
• 64 Markus HS, Levi C, King A. et al. Antiplatelet therapy vs. anticoagulation therapy in cervical artery dissection: The Cervical Artery Dissection in Stroke Study (CADISS) randomized clinical trial final results. JAMA Neurol 2019;
• 65 Byram K, Hajj-Ali RA, Calabrese L. CNS Vasculitis: an approach to differential diagnosis and management. Curr Rheumatol Rep 2018; 20: 37 doi:10.1007/s11926-018-0747-z
• 66 Stone JH, Tuckwell K, Dimonaco S. et al. Trial of Tocilizumab in giant-cell arteritis. N Engl J Med 2017; 377: 317-328 doi:10.1056/NEJMoa1613849